These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29032942)

  • 21. Prediction of Postoperative Hepatic Failure after Liver Resection for Hepatocellular Carcinoma: Significance of the Aspartate Aminotransferase-to-Platelet Ratio Index.
    Tanaka S; Iimuro Y; Hirano T; Hai S; Suzumura K; Fujimoto J
    Hepatogastroenterology; 2014 May; 61(131):755-61. PubMed ID: 26176070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Xu L; Peng ZW; Chen MS; Shi M; Zhang YJ; Guo RP; Lin XJ; Lau WY
    J Hepatol; 2015 Jul; 63(1):122-30. PubMed ID: 25725438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validation and reappraisal of the assessment for retreatment with transarterial chemoembolization score for unresectable non-metastatic hepatocellular carcinoma in a hepatitis b virus-endemic region.
    Ha Y; Lee JB; Shim JH; Kim KM; Lim YS; Yoon HK; Shin YM; Lee HC
    Eur Radiol; 2016 Oct; 26(10):3510-8. PubMed ID: 26747261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma.
    Boulin M; Adam H; Guiu B; Aho LS; Cercueil JP; Di Martino C; Fagnoni P; Minello A; Jouve JL; Hillon P; Bedenne L; Lepage C
    Dig Liver Dis; 2014 Apr; 46(4):358-62. PubMed ID: 24462550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.
    Lee K; Sinn DH; Gwak GY; Cho HC; Jung SH; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Gut Liver; 2016 Sep; 10(5):796-802. PubMed ID: 27114418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The FIB-4 index is a significant prognostic factor in patients with non-B non-C hepatocellular carcinoma after curative surgery.
    Okamura Y; Ashida R; Yamamoto Y; Ito T; Sugiura T; Bekku E; Aramaki T; Uesaka K
    Langenbecks Arch Surg; 2016 Mar; 401(2):195-203. PubMed ID: 26943655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes.
    Casadaban LC; Minocha J; Bui JT; Knuttinen MG; Ray CE; Gaba RC
    AJR Am J Roentgenol; 2016 Mar; 206(3):645-54. PubMed ID: 26901023
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study.
    Chen J; Lai L; Lin Q; Huang W; Cai M; Zhu K; Huang M
    Oncotarget; 2017 Jan; 8(1):408-417. PubMed ID: 27880724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of Patient Survival Following Hepatic Resection in Early-Stage Hepatocellular Carcinoma with Indexed Ratios of Aspartate Aminotransferase to Platelets: A Retrospective Cohort Study.
    Huang J; Yang Y; Xia Y; Liu FC; Liu L; Zhu P; Yuan SX; Gu FM; Fu SY; Zhou WP; Liu H; Jiang BG; Pan ZY
    Cancer Manag Res; 2021; 13():1733-1746. PubMed ID: 33642875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Prognostic Value of aspartate aminotransferase to lymphocyte ratio and systemic immune-inflammation index for Overall Survival of Hepatocellular Carcinoma Patients Treated with palliative Treatments.
    Zhao LY; Yang DD; Ma XK; Liu MM; Wu DH; Zhang XP; Ruan DY; Lin JX; Wen JY; Chen J; Lin Q; Dong M; Qi JJ; Hu PS; Zeng ZL; Chen ZH; Wu XY
    J Cancer; 2019; 10(10):2299-2311. PubMed ID: 31258733
    [No Abstract]   [Full Text] [Related]  

  • 31. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
    Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
    World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma micoRNA-122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma.
    Kim SS; Nam JS; Cho HJ; Won JH; Kim JW; Ji JH; Yang MJ; Park JH; Noh CK; Shin SJ; Lee KM; Cho SW; Cheong JY
    J Gastroenterol Hepatol; 2017 Jan; 32(1):199-207. PubMed ID: 27194671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.
    Takayasu K; Arii S; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Kokudo N; Makuuchi M
    J Hepatol; 2012 Apr; 56(4):886-92. PubMed ID: 22173160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of genetic polymorphism -670A>G in the Fas gene and serum markers AST platelet ratio index, AST/ALT with significant fibrosis and cirrhosis in chronic hepatitis C.
    Deghady A; Abdou A; El-Neanaey WA; Diab I
    Genet Test Mol Biomarkers; 2012 Jun; 16(6):531-5. PubMed ID: 22352690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia.
    Paik N; Sinn DH; Lee JH; Oh IS; Kim JH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Liver Int; 2018 Jan; 38(1):68-75. PubMed ID: 28581248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parametric response mapping cut-off values that predict survival of hepatocellular carcinoma patients after TACE.
    Nörthen A; Asendorf T; Shin HO; Hinrichs JB; Werncke T; Vogel A; Kirstein MM; Wacker FK; Rodt T
    Abdom Radiol (NY); 2018 Dec; 43(12):3288-3300. PubMed ID: 29680967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation.
    Guiu B; Deschamps F; Boulin M; Boige V; Malka D; Ducreux M; Hillon P; de Baère T
    Cardiovasc Intervent Radiol; 2012 Oct; 35(5):1102-8. PubMed ID: 22009578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma.
    Liu J; Zhang W; Niu R; Li Y; Zhou X; Han X
    Saudi Med J; 2020 Apr; 41(4):376-382. PubMed ID: 32291424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma.
    Mähringer-Kunz A; Kloeckner R; Pitton MB; Düber C; Schmidtmann I; Galle PR; Koch S; Weinmann A
    Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1017-1025. PubMed ID: 28197830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma.
    Mähringer-Kunz A; Weinmann A; Schmidtmann I; Koch S; Schotten S; Pinto Dos Santos D; Pitton MB; Dueber C; Galle PR; Kloeckner R
    BMC Cancer; 2018 Apr; 18(1):489. PubMed ID: 29703174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.